tert-Butyl (S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride

Catalog No. :
ACGMDK853
CAS No. :
2453297-16-8
Molecular Formula :
C18H29ClN2O3
Molecular Weight :
356.89

IUPAC Name:tert-butyl (S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride

tert-Butyl (S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$115.00Login to see priceInquiryInquiry
1g95%$311.00Login to see priceInquiryInquiry
5g95%$1072.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride
IUPAC Nametert-butyl (S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride
Molecular FormulaC18H29ClN2O3
Molecular Weight356.89
SMILESCC(C)(C)OC(=O)N1CCN(CC2=CC=CC=C2)C[C@@H]1CCO.Cl
InChI KeyXTHYWYUKBAVIBG-NTISSMGPSA-N
Synonymtert-Butyl (S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride
CAS No.2453297-16-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACGMDK853 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGMDK853 route product structure diagram
    ACGMDK8532453297-16-8
Inquiry

2. ACGMDK853 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACGMDK853 route product structure diagram
    ACGMDK8532453297-16-8
Inquiry

Comments (0)